Compare Novartis AG (NVS) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Valero Energy Corporation — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Valero Energy Corporation trades at $323.5 (market cap $90.68B). The key difference: Novartis AG is far larger — about 3.3× Valero Energy Corporation's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| NVS | VLO | |
|---|---|---|
Market Cap | $298.18B | $90.68B |
Sector | Health | Energy |
52-Week High | $168.62 | $323.92 |
52-Week Low | $119.31 | $133.38 |
Enterprise Value | $339.50B | $94.16B |
Dividend Yield | 3.02% | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Valero Energy (VLO) trades at $298.31, down 1.54% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 29.31% ROE and trades at a P/E of 12.44, below industry averages. Recent news highlights geopolitical tensions supporting refining margins, while Q2 2026 earnings surged on strong refining and renewable diesel performance.
Outlook remains positive with a consensus price target of $324.27, implying 8.7% upside, but risks include volatile oil prices and declining revenue trends. Analyst sentiment is bullish with 55.55% buy ratings, though technical indicators suggest near-term caution amid bearish momentum signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
